Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.
about
Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 BlockadeInitiation and Maintenance of Gastric Cancer: A Focus on CD44 Variant Isoforms and Cancer Stem Cells.Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4.GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cellsCTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion.Inhibitory costimulation and anti-tumor immunity.Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapyCombination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompImmunology and immunotherapy approaches for prostate cancer.Modulation of CTLA-4 and GITR for cancer immunotherapy.Immune regulatory antibodies: are they the next advance?Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma.Lack of intrinsic CTLA-4 expression has minimal effect on regulation of antiviral T-cell immunity.Layers of regulation in induction of mixed chimerism by anti-CD40L.The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer.Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibodyCTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host diseaseBlockade of CTLA-4 (CD152) enhances the murine antibody response to pneumococcal capsular polysaccharides
P2860
Q27487939-707C5E4F-28E6-4133-8321-1D666EECD0ECQ33711746-CFAC4FDC-B437-44A1-854B-28B334CDF0A4Q34554699-58ECFD56-FB35-4593-800A-B9DCE0A55871Q34591128-DD4D2725-66B5-4FD4-B0B7-93C3DA2C3324Q35190928-AC76E320-E81B-4F4E-B66B-1F01AE3FD0A5Q35405162-FB4276EF-0E33-4F15-8787-02E662FDC5E3Q35945339-2D6624B2-C62E-492A-80F4-34666C9D59ACQ36016292-B74C8167-21D0-4678-8768-D8F99A3DCBCAQ36183288-72E6F780-EEB6-405B-BB08-921175AB016EQ36369502-013C18FF-0F7B-4325-8E7A-7EAC88346799Q36375152-23F98507-C52A-40E3-B70F-F97C08D97173Q36786512-ACB15CFF-9559-4664-8B0F-1A5D0548F3C5Q37766483-075BBF49-24E3-4212-9092-13902EF9B5E3Q37778691-6EA2446E-C929-4280-909C-FF24086F29A1Q37809156-3A04B50B-BD7D-42E0-891F-20B0B16268ECQ38160837-2A95FB98-F956-428E-9BB1-6C668DA75FCBQ40721856-9594AC53-EBCB-46A2-893B-CEB2529E9DD3Q42083190-4F4E2F1E-3326-4FF3-B99F-F76D53761958Q47876974-B5A13934-82D1-430C-A8FD-11DB9CF3262AQ56900749-8B2E9531-31C3-48D4-91CD-2C226B9DB037Q56901286-9B01466C-7C80-46A2-B0D6-052578FC5A19Q56902565-27CFBF03-3B97-4542-BB9C-CBC0824D3EDA
P2860
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8(+) T cells independently of CD4(+) T cell help.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Cytotoxic T lymphocyte-associa ...... ndently of CD4(+) T cell help.
@en
type
label
Cytotoxic T lymphocyte-associa ...... ndently of CD4(+) T cell help.
@en
prefLabel
Cytotoxic T lymphocyte-associa ...... ndently of CD4(+) T cell help.
@en
P2093
P2860
P356
P1476
Cytotoxic T lymphocyte-associa ...... endently of CD4(+) T cell help
@en
P2093
P2860
P304
P356
10.1084/JEM.189.7.1157
P407
P577
1999-04-01T00:00:00Z